Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of $169.04 million. The enterprise value is $115.12 million.
Important Dates
The last earnings date was Thursday, March 27, 2025, before market open.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 81.23 million shares outstanding. The number of shares has increased by 0.74% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 81.23M |
| Shares Change (YoY) | +0.74% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 34.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 1.44 |
| PS Ratio | 8.11 |
| Forward PS | n/a |
| PB Ratio | 18.48 |
| P/TBV Ratio | 18.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.60, with a Debt / Equity ratio of 3.51.
| Current Ratio | 2.60 |
| Quick Ratio | 2.60 |
| Debt / Equity | 3.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -23.71 |
Financial Efficiency
Return on equity (ROE) is -162.91% and return on invested capital (ROIC) is -48.98%.
| Return on Equity (ROE) | -162.91% |
| Return on Assets (ROA) | -21.84% |
| Return on Invested Capital (ROIC) | -48.98% |
| Return on Capital Employed (ROCE) | -66.06% |
| Revenue Per Employee | $116,376 |
| Profits Per Employee | -$286,131 |
| Employee Count | 179 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.81% in the last 52 weeks. The beta is 0.86, so Innate Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -16.81% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 2.02 |
| Relative Strength Index (RSI) | 48.63 |
| Average Volume (20 Days) | 16,254 |
Short Selling Information
| Short Interest | 417,095 |
| Short Previous Month | 461,383 |
| Short % of Shares Out | 0.86% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.63 |
Income Statement
In the last 12 months, Innate Pharma had revenue of $20.83 million and -$51.22 million in losses. Loss per share was -$0.63.
| Revenue | 20.83M |
| Gross Profit | -32.98M |
| Operating Income | -53.40M |
| Pretax Income | -8.28M |
| Net Income | -51.22M |
| EBITDA | -51.33M |
| EBIT | -53.40M |
| Loss Per Share | -$0.63 |
Full Income StatementBalance Sheet
The company has $83.62 million in cash and $32.09 million in debt, giving a net cash position of $51.53 million or $0.63 per share.
| Cash & Cash Equivalents | 83.62M |
| Total Debt | 32.09M |
| Net Cash | 51.53M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 9.15M |
| Book Value Per Share | 0.11 |
| Working Capital | 54.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.14 million and capital expenditures -$404,804, giving a free cash flow of -$7.88 million.
| Operating Cash Flow | -7.14M |
| Capital Expenditures | -404,804 |
| Free Cash Flow | -7.88M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is -158.34%, with operating and profit margins of -256.32% and -245.87%.
| Gross Margin | -158.34% |
| Operating Margin | -256.32% |
| Pretax Margin | -245.87% |
| Profit Margin | -245.87% |
| EBITDA Margin | -246.41% |
| EBIT Margin | -256.32% |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.74% |
| Shareholder Yield | -0.74% |
| Earnings Yield | -30.30% |
| FCF Yield | -4.66% |
Analyst Forecast
The average price target for Innate Pharma is $11.50, which is 502.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.50 |
| Price Target Difference | 502.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 58.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -4.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.65 |
| Piotroski F-Score | 2 |